Inclusion Criteria:

• male or female ages 18 and up
• utilizing a regimen of at least two injections daily of insulin and at least two injections daily of Symlin
• able to understand and sign an informed consent form and HIPPA form
• agrees to all study visits and procedures
• HbA1c between >6.5 and <9.0 (inclusive)

Exclusion Criteria:

• history or current diagnosis of chronic disease which in the view of the PI would interfere with adequate involvement in and completion of the requirements of the study
• history of malignancy with in the last five years of study entry (other than basal cell carcinoma)
• current use of any drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine), agents that slow intestinal absorption of nutrients (e.g. a-glucosidase inhibitors) or promotility agents (e.g. metachlopromide)
• any contraindication of Symlin or I-PORT according to the package labeling
• are female and pregnant, lactating or planning to become pregnant during the duration of the trial
• are poorly compliant with their current insulin and/or Symlin regimen, as defined by their HCP
• has history of known hypersensitivity to plastics or polymers
• treatment with any investigational drug within one month prior to enrollment
• myocardial infarction or stroke within six months prior to screening
• initiated use of Symlin pen or any Insulin pen in lieu of a vial in last 4 weeks (pen use is okay as long as they have been using it for at least 4 weeks prior to screening visit)
• female subjects of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, double barrier methods, Intrauterine devices, surgical sterilization or vasectomized partner)
• have confirmed diagnosis of gastroparesis
• have hypoglycemia unawareness